27.07.2016 Views

Osteoporosis Drugs Market Analysis, Size, Share, Growth and Demand Forecast to 2022

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

GLOBAL INDUSTRY INSIGHT:<br />

<strong>Osteoporosis</strong> <strong>Drugs</strong> <strong>Market</strong> Trends, <strong>Size</strong>, <strong>Share</strong>, Development, <strong>Growth</strong><br />

<strong>and</strong> Dem<strong>and</strong> <strong>Forecast</strong> <strong>to</strong> <strong>2022</strong>


Global <strong>Osteoporosis</strong> <strong>Drugs</strong> <strong>Market</strong> Expected <strong>to</strong> Grow at 3.8% CAGR During<br />

2016 – <strong>2022</strong><br />

The global osteoporosis drugs market was valued at $8,835.4 million in 2015 <strong>and</strong> it is expected <strong>to</strong><br />

grow at a CAGR of 3.8% during 2016-<strong>2022</strong>. Among the various classes of osteoporosis drugs, the<br />

rank lig<strong>and</strong> inhibi<strong>to</strong>r segment is expected <strong>to</strong> witness the fastest growth, a CAGR of 4.3% during the<br />

forecast period.<br />

The global osteoporosis drugs market is growing at a significant rate due <strong>to</strong> growing geriatric<br />

population, increasing awareness of osteoporosis <strong>and</strong> increasing healthcare expenditure. The<br />

increasing prevalence of osteoporosis in postmenopausal women <strong>and</strong> the increasing focus on<br />

research & development of new drugs for treatment of osteoporosis are also driving the growth of<br />

the global osteoporosis drugs market.<br />

Explore Report with Detailed TOC at: https://www.psmarketresearch.com/marketanalysis/osteoporosis-drugs-market<br />

<strong>Osteoporosis</strong> disease is the most common bone disease, which occurs due <strong>to</strong> reduced bone mineral<br />

density <strong>and</strong> causes increased risk of fractures <strong>and</strong> fragile bones. It leads <strong>to</strong> abnormally porous<br />

bones such as sponge, which facilitate the weakening of bones <strong>and</strong> painful fracture. Most of the<br />

spine, hip, shoulder <strong>and</strong> forearm fractures occur within aged people of 65 years <strong>and</strong> above.<br />

Some of the signs <strong>and</strong> symp<strong>to</strong>ms of the osteoporosis are falling risk <strong>and</strong> fractures. Diagnostic tests<br />

of osteoporosis include X-Ray test <strong>and</strong> traditional radiography tests, which is further confirmed by<br />

bone density test. <strong>Osteoporosis</strong> disease can be managed by nutrition emphasis, lifestyle<br />

management <strong>and</strong> medicines. The fac<strong>to</strong>rs such as strict regula<strong>to</strong>ry requirement for the approval of<br />

osteoporosis drugs, patent expiry of blockbuster drugs, <strong>and</strong> side-effects <strong>and</strong> complications<br />

associated with osteoporosis drugs are inhibiting the growth of the global market.<br />

Browse Related Research: https://www.psmarketresearch.com/industry-report/healthcare<br />

Geographically, North America dominated the global market of osteoporosis drugs in 2015;<br />

whereas the Asia-Pacific market is expected <strong>to</strong> witness the fastest growth, a CAGR of 4.2% during<br />

the forecast period. This is due <strong>to</strong> the growing geriatric population, increasing awareness of<br />

osteoporosis drugs <strong>and</strong> increasing healthcare expenditure in the region.<br />

© P&S <strong>Market</strong> Research. All rights reserved 2


Global <strong>Osteoporosis</strong> <strong>Drugs</strong> <strong>Market</strong> Expected <strong>to</strong> Grow at 3.8% CAGR During<br />

2016 – <strong>2022</strong><br />

Some of the key companies operating in the global osteoporosis drugs market include Eli Lilly <strong>and</strong><br />

Company, Pfizer Inc., F. Hoffmann-La Roche, Novartis International AG, Merck & Co. Inc. <strong>and</strong><br />

Amgen Inc.<br />

Chapter 1. Research Scope <strong>and</strong> Methodology<br />

1.1 <strong>Market</strong> Definition<br />

1.2 <strong>Market</strong> Scope<br />

1.2.1 Global osteoporosis drugs market breakdown by drug class<br />

1.2.2 Global osteoporosis drugs market breakdown by geography<br />

1.3 Research Methodology <strong>and</strong> Sources<br />

Chapter 2. Executive Summary<br />

2.1 Key Findings<br />

2.2 Research Summary<br />

Chapter 3. <strong>Market</strong> Outlook<br />

3.1 Introduction<br />

3.2 Fac<strong>to</strong>rs Driving <strong>Growth</strong> of the <strong>Market</strong> <strong>and</strong> its Impact on <strong>Market</strong> <strong>Forecast</strong><br />

3.2.1 Impact analysis of drivers on market forecast<br />

3.3 Fac<strong>to</strong>rs Hindering <strong>Growth</strong> of the <strong>Market</strong> <strong>and</strong> its Impact on <strong>Market</strong> <strong>Forecast</strong><br />

3.3.1 Impact analysis of restraints on market forecast<br />

Chapter 4. Global <strong>Osteoporosis</strong> <strong>Drugs</strong> <strong>Market</strong> <strong>Size</strong> <strong>and</strong> <strong>Forecast</strong> (2012 – <strong>2022</strong>)<br />

4.1 Global <strong>Osteoporosis</strong> <strong>Drugs</strong> <strong>Market</strong>, by Drug Class<br />

4.2 Global <strong>Osteoporosis</strong> <strong>Drugs</strong> <strong>Market</strong>, by Region<br />

Chapter 5. Global <strong>Osteoporosis</strong> <strong>Drugs</strong> <strong>Market</strong>, by Drug Class<br />

5.1 Bisphosphonates <strong>Market</strong><br />

5.2 Parathyroid Hormone Therapy <strong>Market</strong><br />

5.3 Selective Estrogen Recep<strong>to</strong>r Modula<strong>to</strong>rs (SERM’s) <strong>Market</strong><br />

© P&S <strong>Market</strong> Research. All rights reserved 3


Global <strong>Osteoporosis</strong> <strong>Drugs</strong> <strong>Market</strong> Expected <strong>to</strong> Grow at 3.8% CAGR During<br />

2016 – <strong>2022</strong><br />

5.4 Rank Lig<strong>and</strong> Inhibi<strong>to</strong>r <strong>Market</strong><br />

5.5 Calci<strong>to</strong>nin <strong>Market</strong><br />

Chapter 6. Global <strong>Osteoporosis</strong> <strong>Drugs</strong> <strong>Market</strong>, by Geography<br />

6.1 North America <strong>Osteoporosis</strong> <strong>Drugs</strong> <strong>Market</strong><br />

6.1.1 North America osteoporosis drugs market, by drug class<br />

6.1.2 North America osteoporosis drugs market, by country<br />

6.2 Europe <strong>Osteoporosis</strong> <strong>Drugs</strong> <strong>Market</strong><br />

6.2.1 Europe osteoporosis drugs market, by drug class<br />

6.2.2 Europe osteoporosis drugs market, by country<br />

6.3 Asia-Pacific <strong>Osteoporosis</strong> <strong>Drugs</strong> <strong>Market</strong><br />

6.3.1 Asia-Pacific osteoporosis drugs market, by drug class<br />

6.3.2 Asia-Pacific osteoporosis drugs market, by country<br />

6.4 Rest of the World (RoW) <strong>Osteoporosis</strong> <strong>Drugs</strong> <strong>Market</strong><br />

6.4.1 RoW osteoporosis drugs market, by drug class<br />

Chapter 7. Competitive Positioning <strong>Analysis</strong><br />

7.1 Porter’s Five Forces of Competitive Position <strong>Analysis</strong><br />

7.1.1 Bargaining power of buyers<br />

7.1.2 Bargaining power of suppliers<br />

7.1.3 Threat of new entrants<br />

7.1.4 Intensity of rivalry<br />

7.1.5 Threat of substitutes<br />

7.2 Competitive Positioning of Key Players in the Global <strong>Osteoporosis</strong> <strong>Drugs</strong> <strong>Market</strong><br />

Chapter 8. Company Profiles <strong>and</strong> Strategic Developments<br />

8.1 Key Company Profile<br />

8.1.1 Pfizer, Inc.<br />

© P&S <strong>Market</strong> Research. All rights reserved 4


Global <strong>Osteoporosis</strong> <strong>Drugs</strong> <strong>Market</strong> Expected <strong>to</strong> Grow at 3.8% CAGR During<br />

2016 – <strong>2022</strong><br />

8.1.1.1 Business overview<br />

8.1.1.2 Product <strong>and</strong> service offerings<br />

8.1.2 Eli Lilly <strong>and</strong> Company<br />

8.1.2.1 Business overview<br />

8.1.2.2 Product <strong>and</strong> service offerings<br />

8.1.3 F. Hoffmann-La Roche<br />

8.1.3.1 Business overview<br />

8.1.3.2 Product <strong>and</strong> service offerings<br />

8.1.4 Novartis International AG<br />

8.1.4.1 Business overview<br />

8.1.4.2 Product <strong>and</strong> service offerings<br />

8.1.5 Merck & Co., Inc.<br />

8.1.5.1 Business overview<br />

8.1.5.2 Product <strong>and</strong> service offerings<br />

8.1.6 Amgen, Inc.<br />

8.1.6.1 Business overview<br />

8.1.6.2 Product <strong>and</strong> service offerings<br />

8.2 Strategic Developments in the <strong>Osteoporosis</strong> <strong>Drugs</strong> <strong>Market</strong><br />

8.2.1 Merger & acquisition<br />

8.2.2 Collaboration/ partnership<br />

8.2.3 Product launch<br />

8.2.4 Client win<br />

8.2.5 Others<br />

Chapter 9. Appendix<br />

9.1 List of Abbreviations<br />

© P&S <strong>Market</strong> Research. All rights reserved 5


Global <strong>Osteoporosis</strong> <strong>Drugs</strong> <strong>Market</strong> Expected <strong>to</strong> Grow at 3.8% CAGR During<br />

2016 – <strong>2022</strong><br />

About P&S <strong>Market</strong> Research<br />

P&S <strong>Market</strong> Research is a market research company, which offers market research <strong>and</strong> consulting services for<br />

various geographies around the globe. We provide market research reports, industry forecasting reports,<br />

business intelligence, <strong>and</strong> research based consulting services across different industry/business verticals.<br />

As one of the <strong>to</strong>p growing market research agency, we’re keen upon providing market l<strong>and</strong>scape <strong>and</strong> accurate<br />

forecasting. Our analysts <strong>and</strong> consultants are proficient with business intelligence <strong>and</strong> market analysis, through<br />

their interaction with leading companies of the concerned domain. We help our clients with B2B market research<br />

<strong>and</strong> assist them in identifying various windows of opportunity, <strong>and</strong> framing informed <strong>and</strong> cus<strong>to</strong>mized business<br />

expansion strategies in different regions.<br />

Contact:<br />

Deep<br />

Assistant – Client Partner<br />

347, 5th Ave. #1402<br />

New York City, NY - 10016<br />

Toll-free: +1-888-778-7886 (USA/Canada)<br />

Email: enquiry@psmarketresearch.com<br />

Web: https://www.psmarketresearch.com<br />

© P&S <strong>Market</strong> Research. All rights reserved 6

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!